Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2026

Conditions

Renal Anemia in Non-dialysis Chronic Kidney Disease

Interventions

DRUG

Pegmolesatide

Pegmolesatide Injection: Specification 1mL: 4.0mg (National Medical Products Administration Approval No. H20230020), administered once every 4 weeks